Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease

• Published in: European journal of surgical oncology 2016-04, Vol.42 (4), p.574-580
• Main Authors: Stevenson, J.D, Watson, J.J, Cool, P, Cribb, G.L, Jenkins, J.P.R, Leahy, M, Gregory, J.J
• Format: Article
• Language: English
• Subjects: Bone Neoplasms - diagnosis; Bone Neoplasms - secondary; Diagnosis, Differential; Female; Hematology, Oncology and Palliative Medicine; Humans; Liposarcoma, Myxoid - diagnosis; Liposarcoma, Myxoid - secondary; Magnetic Resonance Imaging - methods; Male; Metastasis; Middle Aged; MRI; Myxoid liposarcoma; Neoplasm Metastasis; Neoplasm staging; Reproducibility of Results; Sarcoma; Soft Tissue Neoplasms - pathology; Surgery; Whole Body Imaging - methods
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2015.12.011

Abstract Myxoid liposarcomas (MLS) are a subgroup of soft-tissue sarcomas which have a propensity for extra-pulmonary metastases. Conventional radiological staging of soft-tissue sarcomas consists of chest radiographs (CXR) and thoracic computed tomography (CT) for possible chest metastases, supplemented by magnetic resonance imaging (MRI) for local disease. The optimal radiological modality to detect extra-pulmonary metastases for systemic staging has not been proven. We reviewed the efficacy of Whole-Body MRI (WBMRI) for this purpose. 33 WBMRI and simultaneous CT scans were performed in 28 patients suffering from MLS between 2007 and 2015. 38 metastases were identified in seven patients via WBMRI. Osseous lesions predominated (spine, pelvis, chest-wall and long bones), followed by soft-tissue and abdominal lesions. Of the 29 soft-tissue or osseous metastases that were within the field-of-view of the simultaneous CT scans, five soft-tissue and zero osseous metastases were identified using CT. Metastatic disease was detected in three patients solely using WBMRI, which directly influenced their management. WBMRI is a useful adjunct in the detection of extra-pulmonary metastatic disease, which directly alters patient management. WBMRI has demonstrated an ability to identify more sites of metastatic disease compared to CT. WBMRI should be used in two situations. Firstly, at diagnosis where ablative treatment will be required e.g. amputation, when the diagnosis of occult metastasis would change treatment planning. Secondly, at diagnosis of relapse to confirm if it is a solitary site of relapse prior to consideration of metastectomy.